Psychotropic drug purchases during the COVID-19 pandemic in Italy and their relationship with mobility restrictions.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 11 2022
11 11 2022
Historique:
received:
02
05
2022
accepted:
10
10
2022
entrez:
12
11
2022
pubmed:
13
11
2022
medline:
16
11
2022
Statut:
epublish
Résumé
Recent literature on the mental health consequences of social distancing measures has found a substantial increase in self-reported sleep disorders, anxiety and depressive symptoms during lockdown periods. We investigate this issue with data on monthly purchases of psychotropic drugs from the universe of Italian pharmacies during the first wave of the COVID-19 pandemic and find that purchases of mental health-related drugs have increased with respect to 2019. However, the excess volumes do not match the massive increase in anxiety and depressive disorders found in survey-based studies. We also study the interplay between mobility, measured with anonymized mobile phone data, and mental health and report no significant effect of mobility restrictions on antidepressants and anxiolytics purchases during 2020. We provide three potential mechanisms that could drive the discrepancy between self-reported mental health surveys and psychotropic drugs prescription registries: (1) stockpiling practices in the early phases of the pandemic; (2) the adoption of compensatory behavior and (3) unexpressed and unmet needs due to both demand- and supply-side shortages in healthcare services.
Identifiants
pubmed: 36369240
doi: 10.1038/s41598-022-22085-4
pii: 10.1038/s41598-022-22085-4
pmc: PMC9651906
doi:
Substances chimiques
Psychotropic Drugs
0
Antidepressive Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
19336Informations de copyright
© 2022. The Author(s).
Références
JAMA Netw Open. 2020 Sep 1;3(9):e2019686
pubmed: 32876685
J Affect Disord. 2022 Feb 1;298(Pt A):202-208
pubmed: 34732338
Int J Environ Res Public Health. 2020 May 02;17(9):
pubmed: 32370116
Cureus. 2021 Nov 6;13(11):e19313
pubmed: 34900487
J Affect Disord. 2021 Sep 1;292:398-404
pubmed: 34139414
Front Psychiatry. 2020 Aug 07;11:790
pubmed: 32848952
Lancet Psychiatry. 2021 Feb;8(2):141-149
pubmed: 33308420
Sci Rep. 2020 Dec 31;10(1):22457
pubmed: 33384427
F1000Res. 2020 Sep 4;9:1097
pubmed: 33604025
Int J Environ Res Public Health. 2020 Nov 19;17(22):
pubmed: 33228203
J Paediatr Child Health. 2022 Aug;58(8):1359-1365
pubmed: 35435304
Br J Health Psychol. 2021 May;26(2):644-656
pubmed: 33410243
J Sleep Res. 2020 Aug;29(4):e13074
pubmed: 32410272
Soc Psychiatry Psychiatr Epidemiol. 2021 Jan;56(1):165-167
pubmed: 33034669
J Adolesc Health. 2020 Nov;67(5):649-652
pubmed: 32933836
Int Psychogeriatr. 2016 Nov;28(11):1775-1790
pubmed: 27469071
Acta Neuropsychiatr. 2020 Aug;32(4):226-228
pubmed: 32319879
Psychol Med. 2021 Mar 03;:1-9
pubmed: 33653426
Nature. 2020 Aug;584(7820):257-261
pubmed: 32512579
Lancet Psychiatry. 2021 Jul;8(7):610-619
pubmed: 33965057
J Affect Disord. 2022 Jul 15;309:1-8
pubmed: 35472470
Int J Environ Res Public Health. 2020 Jul 04;17(13):
pubmed: 32635422
J Family Med Prim Care. 2020 Oct 30;9(10):5415-5418
pubmed: 33409238
Br J Health Psychol. 2021 May;26(2):535-543
pubmed: 33080090
Nature. 2020 Sep;585(7825):410-413
pubmed: 32365354
Lancet. 2021 Nov 6;398(10312):1700-1712
pubmed: 34634250
JAMA Intern Med. 2021 Jun 1;181(6):861-863
pubmed: 33720285
Front Psychiatry. 2020 Oct 06;11:579985
pubmed: 33132940
Eur Psychiatry. 2020 Sep 28;63(1):e87
pubmed: 32981568
Lancet Public Health. 2022 May;7(5):e406-e416
pubmed: 35298894
PLoS One. 2020 Sep 11;15(9):e0238906
pubmed: 32915878
Psychiatr Serv. 2009 Sep;60(9):1167
pubmed: 19723729
Health Econ. 2021 Sep;30(9):2312-2320
pubmed: 34218496